# Michael White

> Michael White is a debt financing investor at HSBC Innovation Banking backing Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [HSBC Innovation Banking](https://shizune.co/investors/profile/hsbc-innovation-banking)
- Location: San Diego, United States
- Total investments: 4
- Last investment: Dec 2022
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/michael-white-4896225/

Michael White is a National Head of Business Development and Managing Director for Silicon Valley Bank.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Pharmaceutical | 3 | 75% |
| Therapeutics | 2 | 50% |
| Medical | 1 | 25% |
| Biopharma | 1 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Debt Financing | 3 | 75% |
| Post-IPO Debt | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 75% |
| United Kingdom | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aspen Neuroscience | Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $40M | Debt Financing | Dec 21, 2022 |  |
| Viracta Therapeutics | Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application ofthis inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. | $50M | Post-IPO Debt | Nov 05, 2021 |  |
| Numan | Numan is a startup which aims to tackle your tackle problem erectile dysfunction. | $26.8M | Debt Financing |  |  |
| Zogenix | At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatmentof central nervous system disorders and pain. Our lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. |  | Debt Financing |  |  |

4 of 4 investments shown.

## Co-investors
- [Oxford Finance LLC](https://shizune.co/investors/profile/oxford-finance-corporation) — VC Fund, 1 deal together

## About HSBC Innovation Banking

VC Fund · London, United Kingdom

HSBC Innovation Banking provides financial services which also offer flexible banking solutions for start-ups, scale-ups, growth businesses, investors.

5 contacts available at HSBC Innovation Banking.

| Name | Title | Profile |
| --- | --- | --- |
| Clare Mitchell | Director, Fintech | https://shizune.co/investors/profile/clare-mitchell-b063 |
| Emily Turner | CEO | https://shizune.co/investors/profile/emily-turner |
| Erin Platts | CEO (February 2025) | https://shizune.co/investors/profile/erin-platts |
| Matt Perlow | Director | https://shizune.co/investors/profile/matt-perlow-bf47 |
| Michael White | Head of Life Sciences | https://shizune.co/investors/profile/michael-white-b79f |

## Similar investors

### Similar stage
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund
- [The FSE Group](https://shizune.co/investors/profile/finance-south-east) — VC Fund

## FAQ

### What does Michael White invest in?

Michael White invests primarily in Biotechnology, Pharmaceutical and Therapeutics startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michael White last invest?

The most recent investment recorded for Michael White closed in Dec 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co